MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the
US Patent and Trademark Office (USPTO) has granted a patent covering the
Company's cancer compound MOR202. The new patent (US 8,263,746) covers
functional properties of anti-CD38 antibodies and provides additional patent
protection for MorphoSys's HuCAL antibody MOR202. The newly issued patent adds
to the US patent granted earlier this year covering the antibody's protein
sequence as well as pharmaceutical compositions comprising the same. Together,
the two patent families provide strong intellectual property protection for the
MOR202 program. The new patent has a scheduled expiry date in 2025, not
including any potential patent office or regulatory extensions.
Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented:
"Antibodies targeting CD38 are gathering increased interest from the
pharmaceutical industry as a new potential treatment option in multiple myeloma
and other forms of leukemia. As with our other proprietary programs, our goal is
to build a rich scientific, medical and commercial package around MOR202 in
order to lay the groundwork for future partnering. This new patent widens the
scope of our patent position around the MOR202 program by covering the
functional aspects of anti-CD38 antibodies in addition to protecting the
individual antibody sequence."
MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic
target for the treatment of multiple myeloma and certain forms of leukemia. The
fully human HuCAL-antibody is currently being tested in a phase 1/2a trial* in
patients with relapsed/refractory multiple myeloma.
*Supported by the German Federal Ministry of Education and Research as part of
Munich's leading edge cluster m4 - Personalized medicine and targeted therapies
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1662823/539093.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1662823]
Unternehmensinformation / Kurzprofil:
Datum: 06.12.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 210175
Anzahl Zeichen: 5270
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
